Announcements Trials
Browse Landscape

Status

Completed 4

Sponsor Class

OTHER 9INDUSTRY 4

Study Type

Interventional 502Observational 4Expanded_access 1

Sponsor

Cancer Type

Thoracic 4Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Mesothelioma, Malignant 1Lung Neoplasms 1

Interventions

Blood Specimen Collection 31Sorafenib 29Nivolumab 29Bevacizumab 26Data Collection 24Observation 23palbociclib 22Sunitinib 22radium Ra 223 dichloride 20enzalutamide 18Rituximab 18Ipilimumab 16regorafenib 15Drug Therapy 15Trastuzumab 14Docetaxel 14ribociclib 12exemestane 12atezolizumab 12Standard of Care 12darolutamide 11apalutamide 11Leuprolide 11Capecitabine 11Afatinib 11Bortezomib 10Anastrozole 10trastuzumab deruxtecan 9pembrolizumab 9avelumab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Observational × Pemetrexed × Clear all
NCT07141563 2026-01-07

A Study Describing Real-World Effectiveness of Nivolumab + Chemotherapy in Neoadjuvant NSCLC

Bristol-Myers Squibb

Completed
70 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04843007 2024-10-23

Alvopem® (Pemetrexed) Safety Assessment

NanoAlvand

Completed
199 enrolled 21 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung

NCT00497770 2012-05-02

An Observational Study of the Ethnic Impact of Patients Undergoing Second (2nd) Line Treatment for Non-Small Cell Lung Cancer Using Pemetrexed

Eli Lilly and Company

Completed
434 enrolled 23 charts
Thoracic

Lung Neoplasms

NCT00540241 2011-03-29

PERFORMANCE

Eli Lilly and Company

Completed
542 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡